In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)

Neal Irfan; Zain Chagla

doi:10.7326/ACPJ202105180-050

In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)

Ann Intern Med. 2021 May;174(5):JC50. doi: 10.7326/ACPJ202105180-050. Epub 2021 May 4.

Authors

Neal Irfan¹, Zain Chagla¹

Affiliation

¹ McMaster University, Hamilton, Ontario, Canada (N.I., Z.C.).

PMID: 33939483
DOI: 10.7326/ACPJ202105180-050

Abstract

Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021. [Epub ahead of print.] 33725432.

Publication types

Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
ChAdOx1 nCoV-19
Humans
SARS-CoV-2
South Africa
Vaccines*

Substances

COVID-19 Vaccines
Vaccines
ChAdOx1 nCoV-19